T. Rowe Price Associates’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.43M | Buy |
|
|||||
|
2025
Q2 | $1.88M | Sell |
|
|||||
|
2025
Q1 | $8.59M | Sell |
|
|||||
|
2024
Q4 | $50.2M | Sell |
|
|||||
|
2024
Q3 | $36.3M | Buy |
|
|||||
|
2024
Q2 | $36.9M | Sell |
|
|||||
|
2024
Q1 | $37.2M | Buy |
|
|||||
|
2023
Q4 | $33.6M | Sell |
|
|||||
|
2023
Q3 | $38.2M | Sell |
|
|||||
|
2023
Q2 | $106M | Sell |
|
|||||
|
2023
Q1 | $160M | Buy |
|
|||||
|
2022
Q4 | $159M | Sell |
|
|||||
|
2022
Q3 | $180M | Buy |
|
|||||
|
2022
Q2 | $162M | Buy |
|
|||||
|
2022
Q1 | $175M | Buy |
|
|||||
|
2021
Q4 | $112M | Buy |
|
|||||
|
2021
Q3 | $166M | Sell |
|
|||||
|
2021
Q2 | $348M | Buy |
|
|||||
|
2021
Q1 | $162M | Sell |
|
|||||
|
2020
Q4 | $214M | Buy |
|
|||||
|
2020
Q3 | $135M | Buy |
|
|||||
|
2020
Q2 | $70M | Sell |
|
|||||
|
2020
Q1 | $84.2M | Sell |
|
|||||
|
2019
Q4 | $112M | Sell |
|
|||||
|
2019
Q3 | $119M | Sell |
|
|||||
|
2019
Q2 | $149M | Buy |
|
|||||
|
2019
Q1 | $93.3M | Buy |
|
|||||
|
2018
Q4 | $64.5M | Sell |
|
|||||
|
2018
Q3 | $108M | Buy |
|
|||||
|
2018
Q2 | $21.3M | Buy |
|
|||||
|
2016
Q3 | – | Sell |
|
|||||
|
2016
Q2 | $30.1M | Sell |
|
|||||
|
2016
Q1 | $37.5M | Sell |
|
|||||
|
2015
Q4 | $55.7M | Buy |
|